Zymeworks Inc

BetterLife Pharma Inc. is an emerging biotechnology company based in Vancouver, BC, dedicated to developing and commercializing patient-friendly therapeutics for neuropsychiatric and neurological disorders. Their innovative approach aims to eliminate the fear associated with psychedelics by producing non-hallucinogenic medicines to address a wide range of unmet mental health conditions, including anxiety, depression, and PTSD. The company's lead product, BETR001, is a second-generation LSD derivative designed to mimic the therapeutic properties of LSD without its undesirable side effects, such as hallucinations. With a focus on optimizing science and evidence-driven solutions, BetterLife Pharma strives to bring effective treatments to market efficiently, addressing the increasing demand for better mental health solutions. Generated from the website

Healthcord Cryogenics Corp, Canada's oldest and largest cord blood bank, has been a trusted provider of cord blood and tissue banking services for over 25 years, proudly serving families across the nation. The company works with more than 450 hospitals and is both Health Canada approved and AABB accredited, ensuring high-quality service and advanced processing for newborn stem cell storage. Recognized for its commitment to education and quality assurance, Healthcord offers various resources to help families understand the importance of preserving stem cells, which can treat over 80 life-threatening diseases. Their experienced medical team supports families throughout the entire banking process, providing customized care and reliable solutions for stem cell banking needs. Generated from the website

Algernon Pharmaceuticals Inc., based in Vancouver, BC, is a clinical-stage Canadian drug development and repurposing company focused on addressing unmet global medical needs through innovative therapeutic applications. The company employs a cost-effective drug repurposing model that leverages existing compounds with known safety profiles to explore new therapeutic uses, significantly reducing the risk of failure and development time. Algernon's product pipeline includes NP251 (Repirinast), originally developed for asthma, and AP188 (NN-Dimethyltryptamine), which is being advanced for potential treatments in stroke and traumatic brain injury. The company is committed to advancing its research programs and establishing new diagnostic and treatment medical clinics, particularly for Alzheimer's disease, utilizing cutting-edge PET scan technology. Generated from the website